RISPERIDONE-AS risperidone 0.5mg film-coated tablet blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

risperidone, Quantity: 0.5 mg

Disponível em:

Medis Pharma Pty Ltd

DCI (Denominação Comum Internacional):

Risperidone

Forma farmacêutica:

Tablet, film coated

Composição:

Excipient Ingredients: colloidal anhydrous silica; iron oxide red; lactose monohydrate; hypromellose; magnesium stearate; microcrystalline cellulose; maize starch; titanium dioxide; macrogol 400

Via de administração:

Oral

Unidades em pacote:

30 tablets, 60 tablets, 100 tablets, 15 tablets, 20 tablets

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

Risperidone-AS is indicated for the treatment of schizophrenia and related psychoses. Risperidone-AS is indicated for the treatment of behavioural disturbances in dementia. Risperidone-AS is indicated for the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. (See Clinical Trials for maintenance data).

Resumo do produto:

Visual Identification: Red, film-coated, round tablet with "R" engraved on one face and a breakline on the other.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 4 Years; Container Temperature: Store below 25 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2012-09-26